212.612.3030

MARCH 5, 2009

Apex Bioventures to seek shareholder approval to liquidate

Apex Bioventures Acquisition Corporation (PEX on the American Stock Exchange) announced today that its board of directors determined that the company will not consummate a business combination in the time frame required, and that it is advisable that Apex be dissolved. Apex will issue a press release announcing the date of the shareholders meeting at which the Board of Directors will seek shareholder approval for a liquidation plan.
 

Recent News

April 26, 2011

Robert Easton Re-elected a Director of Cepheid
Read more...

Events

June 14, 2011

Robert J. Easton to Moderate Panel on In Vitro Diagnostics
Read more...

Contact Us

Scisive Consulting LP
380 Lexington Avenue
New York, NY 10168
212 612 3030
info@scisive.com